Article
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2016
Klughammer Barbara, Brugger Wolfram, Cappuzzo Federico, Ciuleanu Tudor, Mok Tony, Reck Martin, Tan Eng Huat, Delmar Paul, Klingelschmitt Gaëlle, Yin Anny-Yue, Spleiss Olivia, Wu Lin, Shames David S
Abstract excerpt
INTRODUCTION: Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including erlotinib; however, the ability of less common EGFR mutations to predict efficacy of erlotinib is unclear. METHODS: The efficacy of erlotinib in individual patients with rare EGFR mutations from the MERIT, SATURN, TITAN, TRUST, ATLAS,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.